Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPlus500 Regulatory News (PLUS)

Share Price Information for Plus500 (PLUS)

Share Price is delayed by 15 minutes
Get Live Data
4,790.00    18.00 (0.38%)
Bid:
4,774.00
Ask:
4,778.00
Spread: 4.00 (0.084%)
Market Cap: £3.33b
PLUS Live PriceLast checked at - London Stock Exchange

Intraday Plus500 Share Chart

Notification under Listing Rule 9.6.14(2)

17 Jan 2023 07:00

RNS Number : 8750M
Plus500 Limited
17 January 2023
 

 

17 January 2023

 

Plus500 Ltd.

("Plus500", the "Company" or together with its subsidiaries the "Group")

 

Notification under Listing Rule 9.6.14(2)

Plus500, a global multi-asset fintech group operating proprietary technology-based trading platforms, today announces, pursuant to Listing Rule 9.6.14(2) that Tami Gottlieb, an Independent Non-Executive Director and External Director of Plus500, has been appointed as an Independent Non-Executive Director of Novolog (Pharm-Up 1966) Ltd., a company listed on the Tel-Aviv Stock Exchange.

 

 

For further details

 

Plus500 Ltd.

Elad Even-Chen, Chief Financial Officer

Rob Gurner, Head of Investor Relations

+972 4 8189503

+44 7825 189088

ir@Plus500.com

Brunswick

Charles Pretzlik, Partner

Paul Durman, Partner

+44 20 3128 8549

plus500@brunswickgroup.com

 

 

About Plus500

 

Plus500 is a global multi-asset fintech group operating proprietary technology-based trading platforms. Plus500 offers customers a range of trading products, including OTC ("Over-the-Counter" products, namely Contracts for Difference (CFDs)), share dealing, as well as futures and options on futures.

 

The Group retains operating licences and is regulated in the United Kingdom, Australia, Cyprus, Israel, New Zealand, South Africa, Singapore, the Seychelles, the United States, Estonia and Japan and through its OTC product portfolio, offers more than 2,500 different underlying global financial instruments, comprising equities, indices, commodities, options, ETFs, foreign exchange and cryptocurrencies. Customers of the Group can trade its OTC products in more than 50 countries and in 30 languages. Plus500 does not permit customers located in the US to trade its OTC products.

 

Plus500 does not utilise cold calling techniques and does not offer binary options. Plus500's trading platforms are accessible from multiple operating systems (Windows, iOS and Android) and web browsers. Customer care is and has always been integral to Plus500, as such, OTC customers cannot be subject to negative balances. A free demo account is available on an unlimited basis for OTC trading platform users and sophisticated risk management tools are provided free of charge to manage leveraged exposure, and stop losses to help customers protect profits, while limiting capital losses.

 

Plus500 shares have a premium listing on the Main Market of the London Stock Exchange (symbol: PLUS) and are a constituent of the FTSE 250 index. www.plus500.com.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RDNNKABBQBKDPDD
Date   Source Headline
13th Apr 20233:46 pmRNSHolding(s) in Company
13th Apr 20237:00 amRNSTransaction in Own Shares
12th Apr 20237:00 amRNSTransaction in Own Shares
11th Apr 20237:00 amRNSTransaction in Own Shares
6th Apr 20237:00 amRNSTransaction in Own Shares
5th Apr 20237:00 amRNSTransaction in Own Shares
4th Apr 20237:00 amRNSTransaction in Own Shares
3rd Apr 20237:00 amRNSTransaction in Own Shares
31st Mar 20237:00 amRNSTransaction in Own Shares
30th Mar 20237:00 amRNSTransaction in Own Shares
29th Mar 20237:00 amRNSTransaction in Own Shares
28th Mar 20237:00 amRNSTransaction in Own Shares
27th Mar 20237:00 amRNSTransaction in Own Shares
24th Mar 20237:00 amRNSTransaction in Own Shares
23rd Mar 20237:02 amRNSTransaction in Own Shares
23rd Mar 20237:00 amRNS2022 Annual Report and 2023 Annual General Meeting
22nd Mar 20237:00 amRNSTransaction in Own Shares
21st Mar 20237:00 amRNSTransaction in Own Shares
20th Mar 20237:00 amRNSTransaction in Own Shares
17th Mar 20237:00 amRNSTransaction in Own Shares
16th Mar 20237:00 amRNSTransaction in Own Shares
15th Mar 20237:01 amRNSHolding(s) in Company
15th Mar 20237:00 amRNSTransaction in Own Shares
14th Mar 20237:00 amRNSTransaction in Own Shares
13th Mar 20237:00 amRNSTransaction in Own Shares
10th Mar 20237:00 amRNSTransaction in Own Shares
9th Mar 20237:00 amRNSTransaction in Own Shares
8th Mar 20237:00 amRNSTransaction in Own Shares
7th Mar 20237:00 amRNSTransaction in Own Shares
6th Mar 20237:00 amRNSTransaction in Own Shares
3rd Mar 20237:00 amRNSTransaction in Own Shares
2nd Mar 20237:00 amRNSTransaction in Own Shares
1st Mar 20231:18 pmRNSTR1: notification of major holdings
1st Mar 20237:00 amRNSTransaction in Own Shares
28th Feb 20237:02 amRNSShare Buyback Programme
28th Feb 20237:00 amRNSTransaction in Own Shares
27th Feb 20237:00 amRNSTransaction in Own Shares
24th Feb 20237:00 amRNSTransaction in Own Shares
23rd Feb 20237:00 amRNSTransaction in Own Shares
22nd Feb 20237:00 amRNSTransaction in Own Shares
21st Feb 20237:00 amRNSTransaction in Own Shares
20th Feb 202312:51 pmRNSTR1: Notification of Major Holdings
20th Feb 20237:00 amRNSTransaction in Own Shares
17th Feb 20237:01 amRNSDirector/PDMR Shareholding
17th Feb 20237:00 amRNSTransaction in Own Shares
16th Feb 20237:00 amRNSTransaction in Own Shares
15th Feb 20237:00 amRNSTransaction in Own Shares
14th Feb 20237:01 amRNSTransaction in Own Shares
14th Feb 20237:00 amRNSFinal Results
13th Feb 20237:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.